Clinical Trial Update: Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/Phase 2 clinical trial evaluating the combination of gemcitabine, erlotinib, and nab-paclitaxel in basal-like pancreatic ductal adenocarcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1, Phase 2 | Status: RECRUITING